Senphonix Secures NIH Grant for Continuous Patient Monitoring Wearable

The NIH award, granted through the National Heart, Lung, and Blood Institute, marks the company's second federal research injection in recent weeks, following a September grant from the National Science Foundation. These funds will facilitate software testing, cloud infrastructure scaling, and cybersecurity improvements necessary for SOC 2 Type II compliance. The company aims to address the significant labor burden placed on nursing staff, who can spend up to 20 percent of their shifts manually documenting vital signs.

SleeveSense is designed as a comfortable, wireless arm-worn device that functions both in hospital settings and at home after discharge. By providing continuous data, the platform seeks to identify physiological changes that often precede adverse events, potentially reducing readmission rates. The firm plans to initiate clinical studies in late 2026 or early 2027, with a target of securing FDA 510(k) clearance by mid-2027. The commercial model utilizes a per-patient service fee to eliminate upfront capital costs for healthcare providers, a strategy aimed at overcoming the traditional barriers to hospital-wide technology adoption.